Our Commitment To Progesterone Receptor Positive (PR+) Cancer Patients
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. To fulfill our promise to patients, we have created the ONWARD Clinical Trial network to evaluate our investigational product, Apristor (onapristone xr) in PR+ breast, ovarian, and endometrial cancers.
2L PR+ Metastatic
Breast Cancer (mBCa)
ONWARD 201 will evaluate Apristor in second line (2L) metastatic breast cancer patients who are progesterone receptor positive (PR+) and who have failed prior antiestrogen monotherapy or the combination of an antiestrogen plus a Cdk4/6 inhibitor,
ONWARD 203 will evaluate Apristor in pre-surgical treatment naive breast cancer patients alone and in combination with standard of care agents.
ONWARD 220 will evaluate Apristor in chemotherapy resistant endometrioid endometrial patients.
Investigator Sponsored TRIALS
At Context Therapeutics, we are committed to the advancement of medical and scientific knowledge that addresses the unmet needs of patients with hormone driven cancers.
To learn more about our ISTs, click here.
Developing the next generation of antihormonal therapies to treat breast, prostate, and ovarian cancers.
Apristor is an investigational New Chemical Entity (NCE) for PR+ breast and ovarian cancers.